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ABSTRACT 
Background: Premature coronary artery disease (PCAD) has taken the form of an epidemic 
in developing countries like Pakistan. Genetic information has the potential to create a more 
personalised, prompt, early and accurate risk evaluation. Moreover, the effect of these 
genetic variants on the serum biomarker levels (phenotype) needs to be studied to assess 
their potential causal role in the pathogenesis of PCAD. Objectives were to determine the 
genotypic distribution of  IL-18, TNF-alpha, IL-6 and IL-10 single nucleotide 
polymorphisms (SNPs) in Pakistani PCAD cases and disease free controls and to study the 
effect of these gene polymorphisms on the serum cytokine levels (IL-18,TNF-alpha,IL-6 
and IL-10) and cytokine imbalance (IL-18:IL-10 & TNF-alpha:IL-10). Material and 
Methods: The case-control study was carried out in Army Medical College, National 
University of Sciences and Technology, Islamabad in collaboration with the Cardiovascular 
Genetics Institute, University College London, UK. Subjects (n=340) with > 70% stenosis 
in at least a single major coronary artery on angiography were taken as PCAD cases along 
with 310 angiographically verified controls. ELISA was performed for measuring the 
concentrations of serum IL-18, TNF-alpha, IL-6 and IL-10. Genotyping was done using 
TAQMAN assay. Results: The risk allele frequencies (RAF) of rs1800795 (IL-6) and 
rs187238 (IL-18) cytokine gene promoter SNPs were significantly higher in the PCAD cases 
as compared to the controls. Serum IL-18 and IL-10 levels were significantly greater in the 
IL-18 rs187238 GG genotype patients while serum IL-18 and IL-6 levels were significantly 
higher in patients having the IL-6 rs1800795 CC genotype. IL-18 SNP rs1946519 
significantly altered the IL-18, TNF-alpha, IL-6, IL-18/IL-10 and TNF-alpha/IL-10 ratio 
levels followed by TNF-alpha SNP rs1800629 which significantly altered the serum levels 
of IL-18, IL-18:IL-0 and TNF-alpha:IL-10 ratios. Conclusion: The association of the above 
mentioned SNPs with differential serum cytokine levels especially the pro-/anti-
inflammatory cytokine imbalance points towards their potential causal role in the immune 
inflammatory pathogenic pathway of PCAD.  
Key words: Premature Coronary Artery Disease; Single Nucleotide Polymorphisms; 
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INTRODUCTION: 
              Premature CAD is characterized by >70% blockade in at least one major vessel as 
seen on coronary angiography in patients ≤45 years of age (Dhillon et al., 2004). It is the 
leading cause of morbidity and mortality in young males and females (Rosamond et al., 
2007). PCAD occurs almost a decade earlier in the South Asian population as compared to 
the West (Aggarwal et al., 2014). It is estimated that by the year 2030 the cause of death in 
23.3 million people annually will be Coronary Artery Disease (Vilahur et al., 2014). 
Cytokines are small proteins which are mainly released as a response of the host to disease 
or infection. A number of pro-inflammatory and anti-inflammatory cytokines have been 
identified in the pathogenesis of PCAD and this inflammatory cascade has a role in 
maintaining a delicate balance between various factors that monitor the integrity of the 
vascular system (Kaptoge et al., 2014). Cytokine imbalance and its role in the acceleration 
of atherosclerosis has been highlighted (Khan et al., 2011). Autieri et al., 2012 showed IL-
18:IL-10 can independently predict adverse events in coronary artery disease patients. Li et 
al., 2014 demonstrated that IL-18:IL-10 ratio can also predict CVS events in stable CAD 
patients. IL-18:IL-10 ratio has a vital role in formation of atherosclerotic arterial lesions 
(Xiao-Feng et al.,2009). Patients with CAD demonstrated higher values of TNF-alpha:IL-10 
than the controls (Wojciech et al.,2008).Kaur et al.,2006 suggests that the balance between 
IL-10:TNF-alpha is of more functional significance in cardiac injury. The effect of the 
cytokine genetic variants on the serum biomarker levels (phenotype) need to be studied to 
assess their potential causal role in the pathogenesis of PCAD. While certain studies have 
shown that the cytokine SNPs can lead to alteration in the inflammatory response in CAD 
(Satti et al., 2013) others have negated it (Cho et al., 2013). Thus, a controversy still exists 
regarding the influence of these cytokine gene promoter polymorphisms on the serum 
cytokine levels particularly in the high risk Pakistani subjects. Hence, objectives were to 
determine the genotypic distribution of pro-inflammatory IL-18 (rs1946519 and rs187238), 
TNF-alpha (rs1800629),IL-6 (rs1800795) and anti-inflammatory IL-10 (rs1800871)  gene 
promoter SNPs in PCAD patients and disease free controls and to determine the differential 
serum cytokine levels (IL-18,IL-10,IL-6, TNF-alpha, IL-18:IL-10 & TNF-alpha:IL-10 
ratios) with respect to the genotypic distribution of the selected SNPs in PCAD patients and 
controls. 
Material and Methods:  
The case-control study was conducted in the Chemical Pathology department Army Medical 
College, National University of Sciences and Technology (NUST) Rawalpindi, Pakistan, in 
collaboration with Cardiovascular Genetics (CVG) Institute, University College London 
(UCL), London, United Kingdom (UK) after approval by the Institutional Ethical review 
commitees. A total of 650 subjects aged ≤ 45 years who were stable and were due to undergo 
coronary angiography were consecutively recruited from Armed Forces Institute of 
Cardiology (AFIC) Rawalpindi. The participants had a recent history (< 2 months) of an 
episode of left sided chest pain and were advised angiography by consultant cardiologists 
after evaluation. All participants were citizens of Pakistan. The sampling technique was non-
probability convenience sampling. 340 subjects who displayed >70% stenosis in one 
coronary artery on angiography were categorized as Premature Coronary Artery Disease 
patients. Those patients who had a history of angina, previous MI, infectious, autoimmune 
diseases, hyperlipidemia (familial), heart disease by birth, arthritis, diabetes mellitus, 
expectance of life <12 months along with those not giving informed or written consent were 
not included in the study.  Moreover, 310 age and sex matched controls who were declared 
to be disease free on angiography were recruited. Any subject with acute or chronic ailment 
or taking anti-inflammatory drugs was not included in the control group. Expectant mothers 
or females taking contraceptives were excluded as well. General physical examination 
including detailed history and physical examination was done by a registered medical 
practitioner.             
        Ten ml blood sample was taken from the median cubital vein.  Six ml blood was poured 
into a plain vacutainer tube to separate the serum. Four ml whole blood was poured into 
EDTA tube to extract genomic DNA using Gentra Puregene Blood kit (Qiagen, USA). Serum 
IL-18, TNF-alpha, IL-6 and IL-10 levels were measured using monoclonal antibodies on 
ELISA (Invitrogen). The cytokine SNPs rs187238 (IL-18), rs1800795 (IL-6), rs1800629 
(TNF-alpha), rs1800871 (IL-10) and rs1946519 (IL-18) were genotyped using TAQMAN 
assays according to standard protocols and preformed primers. The reagent volumes for 
TAQMAN genotyping assays, per plate using TAQMAN buffer are shown in supplementary 
table-1(a). 
Table-3.5: Reagent Volumes for TAQMAN Genotyping assays, per plate using 
TAQMAN buffer.  
Reagent Volume (ul) 
TAQMAN Mastermix (Life 
technologies) 
410 
Nuclease Free Water (Sigma) 389.5 / 399.8 
40x/80x SNP Specific Assay (Life 
Technologies) 
20.5 / 10.3 
The volume of SNP specific assay (which contains primers and probes) depends on 
whether it is supplied as 40 or 80x 
 
 
 
 
 The PCR conditions for TAQMAN genotyping assays are summarized in supplementary 
table-1(b).  
Table-3.6:PCR conditions for TAQMAN Genotyping assays 
Temperature Time 
500C 2 mins 
950C 10 mins 
950C 15 sec x 40 cycles 
600C 1 min x 40 cycles 
 
The 5 cytokine gene promoter SNPs were selected from the meta-analyses (Smith et al., 
2015) after a through literature search (Belsky et al., 2013). Details of SNPs selected for our 
study along with the respective references are shown in supplementary Table-2. 
Table 3.2: Selected Cytokine SNPs  
 
 
TNF-alpha= Tumor Necrosis Factor-alpha; IL-18=Interleukin-18; IL-10=Interleukin-10;IL-
6= Interleukin-6. 
 
Gene  SNP SNP 
location 
Risk Allele Odds ratio Reference 
IL-18 rs187238 Promoter G 1.12 Rajesh et 
al.,2015 
IL-18 rs1956519 Promoter G 1.24 Grisoni et 
al.,2008 
TNF-alpha rs1800629 Promoter A 1.13 Wang et 
al.,2015 
IL-10 rs1800871 Promoter C 1.44 Srikanth et 
al.,2012 
IL-6 Rs1800795 Promoter C 1.11 Hou et al.,2015 
      Data analysis was done using standard SPSS software version-21 (SPSS Inc, Chicago, 
Illinois, USA) and R v3.0.3 (R Core Team, 2014). The allelic frequencies of all SNPs were 
checked for Hardy-Weinberg equilibrium (HWE) equation. Kolmogorov-Smirnov test of 
uniformity was applied on the data to assess its distribution. Mean ± SD was calculated for 
continuous normally distributed (Gaussian distribution) variables. Continuous variables were 
compared amongst PCAD cases and controls using Independent t-tests. Categorical variables 
between PCAD cases and controls were compared using chi-square (X2- tests). Association 
between the gene polymorphisms and the serum cytokine levels were assessed by ANOVA 
and Post-hoc Tukey’s test.  A two-tailed p value <0.05 was taken as significant. 
RESULTS: 
     The patients with PCAD had mean ± SD age of 42 ± 3.80 years consisting of 329 males 
and 11 females. Demographic features are given in table-1.  
Table-4.1: Baseline Characteristics of PCAD cases and controls (n=650) 
 
Parameters PCAD patients 
n= 340 
Mean ± SD 
Controls 
n=310 
Mean ± SD 
 
p-value  
Age (y)  42 ± 3.80 39 ± 7.8 0.12 
Sex (m/f) 329/11  298/12 0.66 
Weight (kg)  76.5 ± 12.7* 69.0 ± 11.8 0.303 
Height (m)  1.7 ± 0.12 1.68 ± 0.06  0.301 
Ethnicity  
Punjabis n(%) 
Pathans n(%) 
 
250 (74%) 
  90  (26%) 
 
193 (62%) 
117  (38%) 
 
0.22 
BMI (kg/m2)  26.6 ± 6.7* 24.1 ± 4.03 0.175 
Diastolic BP (mm 
Hg) 
83.0 ± 9.6**  73.1 ± 3.8 0.0001 
Systolic BP (mm of 
Hg) 
124.7 ± 11.0**  112.0 ± 5.1 0.0001 
Smokers  n (%)     197 (58%) **  81 (26%) <0.01 
HTN self n (%)   163 (48%) **   34 (11%) <0.01 
Family history HTN 
n(%) 
   136 (40%)*    37 (12%) <0.05 
Family history 
PCAD n(%) 
  112 (33%)*    28(9%) <0.05 
Family history DM 
n(%) 
    78 (23%)*    25 (8%) <0.05 
Family history IHD 
n(%) 
   136 (40%)**    31(10%) <0.01 
Total Cholesterol 
(mmol/l) 
   4.47 ± 0.87* 4.2 ± 0.77 0.019 
Triglycerides 
(mmol/l) 
   2.4 ± 1.15** 1.9 ± 0.73 0.0001 
LDL-cholesterol  
(mmol/l) 
   2.32 ± 0.77* 2.12 ± 0.75 0.043 
HDL-cholesterol 
(mmol/l) 
   1.07 ± 0.23** 1.24 ± 0.25 0.0001 
VLDL-cholesterol 
(mmol/l) 
   1.07 ± 0.52** 0.87 ± 0.33 0.001 
 
PCAD: Premature Coronary Artery Disease; DM: Diabetes Mellitus; HDL: High Density 
Lipoprotein; LDL: Low Density Lipoprotein; SD=Standard Deviation; CAD: Coronary 
Artery Disease; VLDL: Very Low Density Lipoprotein **p<0.01; *p<0.05 
Categorical variables were compared using a χ2 test while continuous variables were 
compared using independent t-tests. 
 
Most of them were Punjabis 74% and only 26% were Pathans living in the Northern part of 
Pakistan. Body Mass Index (BMI), body weight, systolic & diastolic blood pressure was 
significantly higher in PCAD patients compared to controls (p<0.05). The patients were 
mostly smokers with a positive family history of PCAD and hypertension (p<0.01). The 
genotypic distribution of the 5 cytokine SNPs namely IL-18 rs187238, IL-18 rs1946519, IL-
6 rs1800795, TNF-alpha rs1800629 and IL-10 r1800871 in PCAD patients and controls 
along with their odds ratios and risk allele frequencies are shown in Table-2 & 3 respectively.  
 
 
 Table-4.3: Genotypic distribution of the cytokine SNPs in PCAD cases (n=340) and 
controls (n=310). 
 
TNF-alpha= Tumor Necrosis Factor-alpha; CI=Confidence Interval.  IL-10=Interleukin-
10;IL-6= Interleukin-6; HWE=Hardy-Weinberg Equilibrium;IL-18=Interleukin-18;  
%=percentage; *p<0.05 by applying Chi-Square test;  
*=Risk allele 
 
Gene Genot
ypes 
Cases n 
(%) 
Alleles 
n (%) 
Controls  
n (%)  
Alleles 
n (%) 
 Odds ratio 
risk allele  
(95% CI) 
p-value 
HWE 
TNF-alpha 
rs1800629 
-308 G/A 
AA 
AG 
GG 
10 (3) 
65 (19) 
265 (78) 
G=330 (97) 
*A=75   (22) 
 
 
3 (1) 
48 (15) 
259 (84) 
G=307 (99) 
*A=51 (16) 
1.47  
(1.03-1.79) 
0.12 
IL-18 
rs1946519 
-656 G/T 
GG 
GT 
TT 
 
194 (57) 
108 (32) 
38 (11) 
*G=302(89) 
T=145(42) 
 
152 (51) 
115 (36) 
43 (13) 
*G=267 (86) 
T=157 (51%) 
1.13 
 (0.91-1.43) 
0.11 
IL-18 
rs187238 
-137 G/C 
GG 
GC 
CC 
217 (64) 
116 (34) 
7 (2) 
*G= 334 (98) 
C= 123 (36) 
183 (57) 
108 (37) 
19 (6) 
*G=293 (95) 
C=127 (41) 
1.13  
(1.01-1.43) 
0.09 
IL-6 
rs1800795 
-174 G/C 
CC 
GC 
GG 
13 (4) 
85 (25) 
242 (71) 
*C=98 (29) 
G=326 (96) 
3 (1) 
71 (22) 
236 (77) 
*C=74 (23) 
G=307 (98) 
1.32  
(1.12-1.55) 
0.59 
IL-10 
rs1800871 
-819 C/T 
TT 
CT 
CC 
 
167 (51) 
119 (37) 
54 (12) 
* C=173 (51) 
T= 286 (84) 
162 (49) 
110 (35) 
38 (16) 
 
*C=148 (48) 
T=272 (88) 
1.16  
 (0.81-1.55) 
0.23 
  
 
Table 4.4: Computation of Cytokine SNPs Risk allele Frequencies between PCAD 
cases (n=340) and controls (n=310).  
IL-10=Interleukin-10;IL-6= Interleukin-6; RAF=Risk Allele Frequency; IL-
18=Interleukin-18; CI=Confidence Interval; TNF-alpha= Tumor Necrosis Factor-alpha; 
*p<0.05 by applying Chi-Square test 
 
Among the cytokine SNPs TNF-alpha rs1800629 and IL-6 rs1800795 has the highest odds 
ratio for the risk prediction of PCAD. All the cytokine SNPs complied with Hardy-Weinberg 
equilibrium. The risk allele frequencies of IL-6 (rs1800795) and IL-18 (rs187238) were 
significantly higher in the PCAD cases compared to the disease free controls (p<0.05).   
Gene rs number Cases  
RAF (95% CI) 
Controls  
RAF (95% CI)  
Risk 
Allele 
p-value 
TNF-
alpha 
-308 G/A     
 
rs1800629 
 
0.11 (0.09-0.14) 0.08 (0.06-0.11)   A 0.07 
IL-18 
-656 G/T 
rs1946519 
 
 
0.73 (0.70-0.76) 0.68 (0.64-0.71)   G 0.11 
IL-18 
-137 G/C 
rs187238 
 
0.81 (0.78-0.84) 0.76 (0.73-0.83)   G 0.015* 
IL-6 
-174 G/C 
rs1800795 
 
0.16 (0.14-0.19) 0.12 (0.10-0.15)   C 0.021* 
IL-10 
-819 C/T 
rs1800871 
 
0.70 (0.63-0.70) 0.66 (0.66-0.74)   C 0.19 
      IL-18 levels in serum were significantly greater in the IL-18 rs187238 GG genotype as 
compared to GC & CC genotypes (p<0.05). Mean ± SD values of serum IL-18 levels were 
277.1 ± 4. 63, 257.9 ± 7.57 and 217.8 ± 7.68 pg/ml in GG, GC and CC genotypes 
respectively. Interestingly serum IL-10 level was also significantly greater in the GG 
homozygotes as compared to the GC and CC genotypes (p<0.05).  Mean ± SD values of IL-
10 levels were 0.88 ± 0.07, 0.85 ± 0.12 and 0.81 ± 0.12 in GG, GC and CC genotypes 
respectively. Comparison of serum IL-18 & IL-10 cytokine levels with respect to the 
genotypic distribution of IL-18 rs187238 SNP is shown in Fig-1 (a).  
   Serum IL-18, TNF-alpha and serum IL-6 levels were significantly higher in the IL-18 
rs1946519 GG genotype patients as compared to GT and TT genotypes (p<0.05). 
Interestingly the serum IL-18:IL-10 and TNF-alpha:IL-10 ratios were significantly higher in 
GG genotype patients as compared to GT and TT genotypes (p<0.01). The comparison of 
serum IL-18, TNF-alpha, IL-6, IL-18:IL-10 and TNF-alpha:IL-10 ratios with respect to the 
genotypic distribution of IL-18 rs1946519 SNP is shown in Fig-1 (b). Detailed serum IL-18, 
TNF-alpha, IL-6, IL-18:IL-10 and TNF-alpha:IL-10 ratios with respect to the genotypic 
distribution of IL-18 rs1946519 SNP are shown in supplementary table-3. 
     There was no significant difference in the serum IL-18, IL-6, TNF-alpha, IL-10, IL-18/IL-
10 and TNF-alpha:IL-10 ratios with respect to the genotypic distribution of IL-10 rs1800871 
SNP in the PCAD patients (p>0.05). Serum IL-18 and IL-6 levels were significantly higher 
in patients having the IL-6 rs1800795 CC genotype as compared to GC and GG genotypes 
(p<0.05). Mean ± SE values of serum IL-18 levels were 283.4 ± 31.1,  274 ± 30.3 and 262.4 
± 19.93pg/ml while serum IL-6 levels were 3.8 ± 1.0, 2.9 ± 0.64 and 1.4 ± 0.60 ng/dl  in CC, 
GC and GG genotypes respectively. Comparison of serum IL-18 and IL-6 cytokine levels 
with respect to the genotypic distribution of IL-6 rs1800795 SNP is shown in Fig-1 (c).  
        Serum IL-18, IL-18:IL-10 and TNF-alpha:IL-10 ratios were significantly higher in the 
TNF-alpha rs1800629 A-allele homozygotes as compared to GA and GG genotypes (p<0.05) 
as shown in fig-1(d). IL-18 SNP rs1946519 had the maximum influence on the serum 
cytokine levels by significantly altering IL-18, TNF-alpha, IL-6, IL-18:IL-10 and TNF-
alpha:IL-10 ratio levels followed by TNF-alpha SNP rs1800629  which significantly altered 
the serum levels of IL-18, IL-18:IL-0 and TNF-alpha:IL-10 ratios.  
DISCUSSION: 
                  The risk allele of IL-18 rs187238 and IL-18 rs1946519 SNPs in our population 
was G based on odds ratio of the allele for PCAD. This is in agreement with a study carried 
out on South Asian population by Kumar et al., 2015. The risk allele frequencies of the above 
mentioned SNPs were significantly raised in the PCAD cases as compared to the disease free 
controls. While some studies support the results of our study showing significant association 
of the IL-18 rs187238 and IL-18 rs1946519 SNPs with CAD (Hernesniemi et al., 2010) 
others have shown no such association (Shayan et al., 2007). A study done on Brazilian 
patients has also not shown any association of these SNPs with the cardiovascular risk factors 
(Farias et al., 2013). Genotypic distribution of the IL-6 rs1800795 SNP was also determined 
in our study subjects. The risk allele for IL-6 rs1800795 our study was C. This is in agreement 
with another study carried out in the high risk Pakistani families where the minor allele C 
showed high prevalence in cases compared to controls (Satti et al., 2013). As far as the risk 
allele frequency of the IL-6 rs1800795 SNP and its association with CAD is concerned the 
results in different population remained discrepant. While a strong association of the risk 
allele C was demonstrated with CAD in the Chinese (Hou et al., 2015) and Indians 
(Bhanushali et al.,2013) no such association was seen in the Tunisians (Ghazouani et 
al.,2011). The Northwick Park Heart study on the other hand showed that the IL-6 rs1800795 
GC (heterozygotes) were significantly at a greater risk to develop CAD as compared to the 
CC homozygotes (Humphries et al.,2001). 
          The risk allele for TNF-alpha rs1800629 was A in our study group. However, the risk 
allele frequency of TNF-alpha rs1800629 did not vary significantly between the PCAD 
patients and controls. The observation in our study conflicts with the results seen in a recent 
study carried out to see the association of TNF-alpha rs1800629 SNP with familial CAD 
(Hussain et al.,2015) and another study on Italian subjects (Szalai et al.,2002) and Indians 
(Bhanushali et al.,2013). However, it agrees with some studies where there was no 
association between the TNF-alpha rs1800629 SNP and CAD outcomes (Elahi et al.,2009) 
neither was there any variation in the risk effects of the TNF-alpha rs1800629 SNP between 
Caucasians and Asians (Chu et al.,2012). 
        The risk allele in IL-10 rs1800871 SNP was C in our study subjects however the RAF 
did not differ significantly between PCAD cases and controls. The risk allele in the Chinese 
Han population on the other hand was identified as T for the IL-10 rs1800871 SNP (Yong et 
al., 2015) and it showed strong significant association with valvular calcification. The risk 
allele frequency of IL-10 rs1800871 was not raised significantly in the PCAD cases as 
compared to disease free controls in our study. This conflicts with the observations in a study 
carried out on CAD patients by Afzal et al., 2012 where the allele frequency of the protective 
allele T was significantly raised in the controls as compared to the cases. However, our results 
are in agreement with the study conducted by Koch et al., 2001 where the IL-10 
polymorphisms did not associate significantly with the risk of CAD.  
       The cause of these inter-ethnic variations is not definitively known as yet but some of 
the probable reasons of difference in the association of SNPs with a disease trait are allele 
frequency differences among ethnicities and variable patterns of linkage disequilibrium 
resulting in ‘tag SNPs’ which differ by population strata (Smith et al., 2015). These 
observations form a strong basis of the impact of ethnic descent and deviation from the HWE 
on the variable distribution of cytokine gene promoter SNPs in PCAD. Knowledge of these 
cytokine allele frequencies in our Pakistani subjects is essential because they may be a major 
contributing factor towards racial disparities with respect to the mortality and morbidity of 
low grade inflammatory disease like PCAD (VanDyke et al., 2009). 
           Serum cytokines are in part a heritable trait (Matteini et al., 2014). To the best of our 
knowledge this is the first comprehensive study which has demonstrated the effect of the 
pro-inflammatory and anti-inflammatory cytokine gene variants on the serum cytokine levels 
with respect to the risk allele distribution. The serum IL-18 level was significantly raised in 
the GG genotype of the IL-18 rs187238 SNP in PCAD patients in our study as compared to 
the GC and CC genotypes. This observation is supported by another study which supports 
the role of IL-18 rs187238 SNP in variable expression of IL-18 (Tiret et al.,2005).Contrary 
to this it was reported in a previous study that IL-18 levels were not influenced by the IL-18 
rs187238 genotypes (Opstad et al.,2011). The conflicting results point to the need of 
identification of the actual causal variants in the IL-18 gene. Interestingly, serum IL-10 was 
raised significantly in the risk allele homozygotes GG suggesting that the IL-18 rs187238 G 
allele probably has an effect on the enhancers regulating the transcription of the IL-10 gene 
promoter region leading to the increase in the anti-inflammatory cytokine production to 
counter the inflammatory response. The IL-18 rs1946519 SNP GG genotype was 
significantly associated with higher pro-inflammatory cytokine levels (IL-18, TNF-alpha and 
IL-6) and cytokine imbalance. This cytokine imbalance and greater susceptibility to the 
disease is probably because of the simultaneous action of the IL-18 rs1946519 gene variant 
on the transcription regulation factors of the pro- and anti-inflammatory cytokines mainly by 
promoting binding of the nuclear factors to transcription regulatory sites of these cytokines 
leading to variable mRNA expression. Our observation is supported by a study which states 
that a single enhancer or silencer can regulate multiple genes at a time (Mohrs et al., 2009). 
               The IL-10 serum levels were not significantly different in the risk allele carriers of 
the IL-10 rs1800871 SNP as compared to the non-carriers in our study. On the contrary a 
study shows that IL-10 levels are influenced by IL-10 gene variants including rs1800871 
SNP (Jose Carlos et al., 2015). A possible explanation for this difference might be that the 
IL-10 rs1800871 might not be the functional variant and might just be in close proximity or 
in linkage disequilibrium with the functional variant. The IL-10 gene 5′-flanking sequence 
has three SNPs upstream from the transcriptional start site, at positions −1082 (G/A: 
rs1800896), −819 (C/T), and −592 (C/A: rs1800872), that regulate IL10 expression and they 
all are in strong LD (Maziad et al., 2010) making it difficult to identify the exact locus that 
is most influencing the serum levels of IL-10. Another probable explanation could be the 
suppression of IL-10 production via activation of the STAT group of transcription regulation 
factors (repressors) by the IL-10 gene variant (Kahraman et al., 2006). More detailed 
functional studies including haplotype analyses with denser SNP panels and direct 
sequencing will be required to localize the causal variants in this region to unravel the exact 
mechanism. 
       IL-6 rs1800795 SNP significantly affected the serum IL-18 and IL-6 levels as they were 
higher in the risk allele C carriers of this SNP. Since this is a promoter region polymorphism 
certain researchers suggest that it might directly affect at the transcription regulation factors 
(activators) leading to altered production of IL-6 (Satti et al.,2013) or that it might be tagging 
a gene variant affecting the transcriptional regulation of IL-18 production (Matteini et al., 
2014). Some studies suggest that the IL-6 rs1800795 SNP might be altering the methylation 
levels of the IL-6 gene promoter (Yang et al., 2012). The transcriptional silencing occurs as 
a result of hypermethylation of gene promoters while overexpression is a result of DNA 
hypomethylation. Previous studies have shown that various inflammatory cytokines are 
regulated via epigenetic mechanisms in human cancers (Tekpli et al., 2013) however, till 
today, the information regarding the epigenetic mechanisms regulating cytokines in PCAD 
is scarce and needs due attention.  
         The risk allele A carriers of TNF-alpha rs1800629 did not have significantly higher 
levels of serum TNF-alpha in PCAD patients as compared to the non-carriers in our study. 
A probable reason for this is that a study demonstrates that three genetic variants in the gene 
promoter of TNF-alpha gene act synergistically to determine the functioning of the TNF-
alpha gene (Cui et al., 2012). Certain studies show that the A allele of TNF-alpha rs1800629 
does not affect TNF-alpha gene transcription (Elahi et al., 2009). There have been conflicting 
results regarding the risk allele of TNF-alpha rs1800629 also as some studies have shown 
the higher TNF-alpha production from G/A heterozygotes and GG homozygotes. Therefore, 
there is a possibility that the TNF-alpha production might be under the influence of 
multifactorial regulatory process. On the other hand serum IL-18, IL-18:IL-10 and TNF-
alpha:IL-10 ratios were significantly higher in the G allele carriers of TNF-alpha rs1800629 
SNP. A probable explanation could be that the SNP is in close proximity to or tagging a SNP 
affecting the transcription binding activity in the IL-18, TNF-alpha & IL-10 gene promoter 
regions enhancing the production of IL-18 and repressing production of IL-10 causing pro-
.anti-inflammatory imbalance in PCAD. Cytokine polymorphisms have been shown to 
influence transcription, translation and levels of proteins in the atherosclerotic plaque 
(Cappuccilli et al., 2014). Our study has shown that inherited genetic variations in cytokine 
genes can affect the phenotypic traits like inflammatory biomarker levels in PCAD which 
can become the therapeutic targets in future. The serum cytokine levels did not vary 
significantly with respect to the genotypic distribution of the 5 cytokine gene promoter SNPs 
in the disease free controls of our study. 
CONCLUSIONS: 
The cytokine gene promoter SNPs (genotypic trait) have significant influence on the serum 
cytokine levels and the pro-/anti-inflammatory cytokine imbalance (phenotypic trait) which 
makes them making them important therapeutic and epipeutic targets in PCAD patients.  
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FIGURE LEGENDS: 
Fig-1 (a) Bar chart showing comparison of serum IL-18 and IL-10 cytokine levels with 
respect to the genotypic distribution of IL-18 rs187238 SNP by applying One-way 
ANOVA analysis and Post Hoc Tukey’s test. 
Fig-1 (b) Bar chart showing comparison of serum IL-18, TNF-alpha, IL-6, IL-18/IL-10 
and TNF-alpha/IL-10 ratios with respect to the genotypic distribution of IL-18 rs1946519 
SNP by applying One-way ANOVA analysis and Post Hoc Tukey’s test. 
Fig-1(c) Bar Chart showing comparison of serum IL-18 and IL-6 cytokine levels with 
respect to the genotypic distribution of IL-6 rs1800795 SNP by applying One-way 
ANOVA analysis and Post Hoc Tukey’s test. 
Fig-1(d) Bar chart showing comparison of serum IL-18, IL-18/IL-10 and TNF-alpha/IL-
10 ratios with respect to the genotypic distribution of TNF-alpha rs1800629 SNP by 
applying One-way ANOVA analysis and Post Hoc Tukey’s test. 
 
